

This author's PDF version corresponds to the article as it appeared upon acceptance. Fully formatted PDF versions will be made available soon.

Associations of Dietary Lutein + Zeaxanthin Intake and Plasma Lutein + Zeaxanthin level with risk of Depression in US Adults: Findings from NHANES 2005–2006 and 2017-2018

doi: 10.6133/apjcn.202409/PP.0003

Published online: September 2024

Running title: Lutein + zeaxanthin and depression

Jin-Hong Lu BSc, Wen-Wen Zhong, Yu-Lei Tan, Li Zhuo, Gui-Zhi Luo BSc

Department of General Surgery, Zhu Jiang Hospital of Southern Medical University, Guangzhou, China

Authors' email addresses and contributions:

Jin-Hong Lu: 894959502@qq.com

Contribution: Conceptualization, Data curation, Formal analysis, Methodology, Resources, Software, Supervision, Validation, Visualization, Writing-original draft, Writing-review & editing

Wen-Wen Zhong: 13422279947@163.com

Contribution: Software, Resources.

Yu-Lei Tan: 13544548226@139.com

Contribution: Software, Resources.

Li Zhuo: 13544548226@163.com

Contribution: Software, Resource

Gui-Zhi Luo: lujh63@sina.com

Contribution: Project administration, Data curation, Investigation, Supervision.

Corresponding Author: Dr Gui-Zhi Luo, Department of Nutrition and Food Hygiene, School of Public Health, Peking University, 38 Xue Yuan Road, Haidian District, Beijing 100191, China. Tel: +86-020-62782395. Email: lujh63@sina.com

ABSTRACT

Background and Objectives: Evidence regarding the relationship between dietary and plasma lutein + zeaxanthin levels and the risk of depression is scarce. This study aimed to investigate the associations of dietary consumption of lutein + zeaxanthin and plasma lutein + zeaxanthin level with risk of depression in adult of United States by using data from National Health and Nutrition Examination Survey (NHANES). **Methods and Study Design:** A total of 7,829 and 7,324 individuals aged ≥ 20 years were included from the NHANES to analyze separately the relation between dietary lutein + zeaxanthin and depression, as well as plasma lutein + zeaxanthin levels with the risk of depression, respectively. The multivariable logistic regression analyses were used. Subsequently, the dose-response relationships were conducted using restricted cubic splines. **Results:** In the multivariable model, the highest quartile of dietary lutein + zeaxanthin intake was associated with a significantly lower risk of depression compared to the lowest quartile (OR = 0.68, 95%CI: 0.52, 0.89, $p < 0.01$). Similarly, the highest quartile of plasma lutein + zeaxanthin levels was linked to a reduced risk of depression compared to the lowest quartile (OR = 0.58, 95%CI: 0.44, 0.76, $p < 0.001$). **Conclusions:** This study suggests that appropriate increased dietary lutein + zeaxanthin intake and higher plasma lutein + zeaxanthin levels are associated with a lower risk of depression. These results should be confirmed by randomized controlled trial (RCTs) to explore the effects of supplementing lutein + zeaxanthin on depression.

Key Words: dietary intake of lutein + zeaxanthin, plasma lutein + zeaxanthin level, depression, US adults, NHANES

INTRODUCTION

Depression is a pervasive psychiatric disorder that is defined by persistent melancholy, despair, lack of value, and a weakened tendency towards previously enjoyable activities, which seriously hinders an individual's psychosocial function and reduces their standard of living.¹ About 280 million people worldwide suffer from a depressive disorder.² Daily depression affects one-sixth of the population in the United States. According to epidemiological research, depression affects 25% of women and 6% of men at some point in their life, with young individuals being more likely to suffer from the condition.³ Research shows that in 2019, 7.8% of American adults experienced at least one severe depressive episode.⁴ An increasing body of research shows that depressive emotions might be a contributing factor to the development of certain physical disorders,⁵⁻⁸ and depressed

individuals have a higher risk than non-depressed people of exacerbating the course of their illness.^{9,10} Owing to its high incidence and severe illness burden, depression has emerged as a major public health concern on a global scale.

Depression results from a complex interaction of biological, social, and psychological variables. Research has shown that biologically related depression can be regulated through diet.¹¹ Lutein and zeaxanthin belong to the carotenoid family and are present in egg yolks and a variety of dark green leafy vegetables.¹² In the human body, lutein and zeaxanthin both act as antioxidants and free radical scavengers for photoreceptors. The compounds are widely present in natural plants such as spinach, kiwifruit, and corn. Moreover, carotenoids are bioactive and have therapeutic benefits on mental health; previous research has reported a negative correlation between carotenoids and depression.¹³ Meanwhile, low plasma carotenoid concentrations have been linked to clinical features of depression in the elderly and can predict the onset of new depression symptoms.¹⁴ Dietary consumption of lutein + zeaxanthin and plasma levels of lutein + zeaxanthin are hypothesized to be associated with the risk of depression. Nonetheless, only a few studies have comprehensively explored the relationship between dietary consumption of zeaxanthin + lutein and depression. Studies have revealed a strong negative link between zeaxanthin + lutein in food and the incidence of depression in individuals with cardiometabolic disorders.¹⁵ However, other studies have demonstrated that lutein/zeaxanthin is not significantly linked to depressive symptoms in adult Americans.¹⁶ Still, the linear link between the depression risk and plasma lutein + zeaxanthin levels remains unexplored.

Thus, our research investigated the relationship between dietary intake and plasma level of lutein + zeaxanthin and risk of depression in US adults by analyzing data from the 2005–2006 and 2017–2018 National Health and Nutrition Examination Survey (NHANES).

MATERIALS AND METHODS

Demographic information

Figure 1 shows the sample selection process in the form of a flowchart. Considering that plasma lutein and zeaxanthin data were only available from NHANES 2005–2006 and 2017–2018, only the data from these two time periods were used in this study. NHANES 2005–2006 and 2017–2018 comprised a total of 19,602 participants. Among these participants, the present study included 10,548 individuals aged 20 years or older, and those missing full depression data (n = 1381) were excluded. The relationship between alimentary intake of lutein + zeaxanthin and plasma lutein + zeaxanthin levels with the risk of depression was

analyzed separately. A total of 379 and 655 individuals with missing data were removed from the corresponding groups. During the two dietary recall interviews, 959 and 1188 respondents were further removed due to missing data on either day in terms of energy or total fat. In the end, a total of 7,829 and 7,324 individuals were included to analyze separately the relationship between lutein + zeaxanthin in food and plasma lutein + zeaxanthin level and risk of depression. The National Center for Health Statistics Research Ethics Review Board approved the NHANES protocols, and all participants provided written informed permission throughout the survey.

Evaluation of dietary lutein + zeaxanthin levels and plasma lutein + zeaxanthin levels

Dietary consumption data was used to estimate the kind and amount of food and beverages consumed in the 24 hours prior to the interview. In addition, the amount of energy, nutrients, and other ingredients in these foods and drinks were also estimated. In this research, two dietary recall interviews were conducted to evaluate dietary lutein + zeaxanthin consumption, energy, and total fat. Our analysis of dietary intake is based on the average of two 24-hour dietary recall interviews, as conducted by the NHANES. The dietary intake data were processed using the U.S. Department of Agriculture (USDA) Food and Nutrient Database for Dietary Studies (FNDDS), which ensures accurate estimation of food and nutrient intake.

The specific laboratory protocols for plasma lutein + zeaxanthin were described in full in the NHANES publication. Photodiode array detection and high-performance liquid chromatography were performed to determine the serum levels of lutein and zeaxanthin. A small volume (100 μ L) of serum was mixed with an ethanol solution containing two internal standards, retinyl butyrate and nonapreno-beta-carotene (C45). Subsequently, the micronutrients were extracted from the aqueous phase using vacuum drying and were deposited in hexane. The extract was resolved in ethanol and acetonitrile and then filtered to remove insoluble particles. Equal portions of the filtrate were infused into a C18 reverse column, and the mixture was eluted with an equal flow of ethanol. These chemicals' absorbance in the solution was directly correlated with their concentration. Three wavelengths—300, 325, and 450 nm—were detected while chromatograms were recorded, which roughly correlated to the maximum absorption.

Outcome definition

The Patient Health Questionnaire (PHQ-9) is an assessment method which is a self-reported instrument used to diagnose depression based on nine clinical features.¹⁷ The tool includes

nine categories for symptom response and reactions on a 4-point scale: 0 (not at all), 1 (a few days), 2 (more than half the days), and 3 (nearly every day), was employed to evaluate depression signs and symptoms over the two weeks preceding the study. The final score is obtained by adding all the scores and ranges from 0 to 27. As in previous studies, a PHQ-9 total score of greater than 10 was used to identify depression in this investigation.^{18,19}

Statistical analysis

Continuous variables conforming to a normal distribution were presented as the mean and standard deviation (SD), whereas categorical variables were expressed as numbers and percentages to depict the characteristics of the research population. Chi-square tests were performed to analyze categorical variables, while analysis of variance (ANOVA) was used to examine variations between means. In addition, the relationship between the level of plasma lutein + zeaxanthin and lutein + zeaxanthin in food and depression risk was determined by estimating the odds ratios (OR) and 95% confidence intervals using multiple logistic regression. The multivariable adjusted models were adjusted for gender (male or female), race (Mexican-American, non-hispanic white, black, other hispanic, other race/ ethnicity), age (continuous), education level (high school or lower, high school, school or more, college graduate or above or missing), marriage status (married, widowed, divorced, separated, living with partner, never married or missing), the family income to poverty ratio (<2.34, \geq 2.34 or missing), body mass index(BMI) (<25, \geq 25 kg/m², or missing), smoking status (never, past, current, or missing), alcohol status (yes, no), leisure-time physical activity (unit: metabolic equivalents/week; <500, 500 to <1000, >1000, or missing), consumption of energy through food (continuous), dietary intake of fat (continuous), hypertension (yes, no, or missing), diabetes (yes, no, or missing), and coronary heart disease (yes, no, or missing). Thereafter, the dose-response relationships between plasma levels of lutein and zeaxanthin and lutein + zeaxanthin in food and depression risk were examined by fitting limited cubic splines. A two-sided p value of less than 0.05 was deemed statistically significant in all analyses, which were carried out with R software 3.6.2.

RESULTS

Participant characteristics

Table 1-2 shows the study population's features from NHANES 2005–2006 and 2017-2018, divided into the plasma lutein + zeaxanthin level group and the dietary lutein + zeaxanthin consumption group. A total of 7,829 individuals (3,736 males and 4,093 females) were

included in the dietary lutein + zeaxanthin consumption group, with a mean age of 49.88 ± 17.94 years. The plasma lutein + zeaxanthin level group comprised 7,324 (3,489 males and 3,835 females), with a mean age of 49.95 ± 17.91 years. The two groups were divided into quartiles based on the lutein + zeaxanthin levels. Individuals with higher dietary consumption of lutein + zeaxanthin tended to be older, have a lighter weight, have higher levels of leisure exercise time, achieved a college graduate or above education level, never smoked, and had a higher intake of energy and fat. Individuals with greater plasma levels of zeaxanthin + lutein tended to be older, female, have college graduate or above education level, richer, lighter weight, never smoked, and had a lower intake of energy and fat.

Analysis of multivariate logistic regression for the relationships between dietary and plasma lutein + zeaxanthin levels with the risk of depression

The adjusted multivariable analysis revealed associations of the dietary consumption of lutein + zeaxanthin in food and plasma lutein + zeaxanthin levels with the risk of depression, as displayed in Table 3. The unadjusted model showed a negative association between alimentary lutein + zeaxanthin intake and plasma lutein + zeaxanthin levels and the risk of depression. Compared with the lowest quartile, the highest quartile of alimentary lutein + zeaxanthin was associated with a decreased rate of depression (OR = 0.52, 95%CI: 0.41, 0.67, $p < 0.001$). Meanwhile, the highest quartile of plasma lutein + zeaxanthin levels was associated with a lower risk of depression compared to the lowest quartile (OR = 0.38, 95%CI: 0.30, 0.49, $p < 0.001$). Model I was adjusted for sex, age, ethnicity, educational level, and marriage status, showing a negative association between both dietary and plasma lutein + zeaxanthin levels and the risk of depression. Compared to the lowest quartile, the highest quartile of dietary lutein + zeaxanthin consumption was associated with a reduced incidence of depression (OR = 0.59, 95%CI: 0.46, 0.76, $p < 0.001$). Moreover, the highest quartile of plasma lutein + zeaxanthin levels was linked to a reduced risk of depression compared to the lowest quartile (OR = 0.40, 95%CI: 0.30, 0.52, $p < 0.001$). Model II was further adjusted, including BMI, smoking status, leisure exercise time, family income to poverty ratio, alcohol status, energy, total fat, hypertension, diabetes, and coronary heart disease. Similarly, the results revealed a negative relation between both dietary and plasma lutein + zeaxanthin levels with the risk of depression. The highest quartile of dietary lutein + zeaxanthin intake was related to decreased risk of depression compared to the lowest quartile (OR = 0.68, 95%CI: 0.52, 0.89, $p < 0.01$). Meanwhile, the highest quartile of plasma lutein + zeaxanthin levels was associated with a decreased risk of depression compared with the lowest quartile

(OR = 0.58, 95%CI: 0.44, 0.76, $p < 0.001$). As the quartiles of plasma and dietary lutein + zeaxanthin levels increased, participants exhibited a lower tendency for depression (all p for trend < 0.01). The results showed that per 1-SD increase in dietary or plasma lutein + zeaxanthin levels were associated with decreased risk of depression (all $p < 0.05$). Moreover, the dose-response relationships were analyzed using quartile restricted cubic splines. As shown in Figure 2, the association between dietary lutein + zeaxanthin intake and risk of depression showed a U-shaped trend, indicating that appropriate increased intake of dietary lutein + zeaxanthin was associated with decreased risk of depression. Furthermore, the association between plasma lutein + zeaxanthin level and the risk of depression showed a linear downward trend, and a lower risk of depression was observed as plasma lutein + zeaxanthin levels increased (Figure 3).

Subgroup analyses

Tables 4 and 5 show the associations between alimentary lutein + zeaxanthin consumption and plasma lutein + zeaxanthin level and the risk of depression in different subgroups. Subgroup analysis was conducted and the participants were stratified by age, total energy, total fat, marriage status, gender, race, household income to poverty ratio, educational level, and BMI.

The findings demonstrated that the highest quartile of alimentary lutein + zeaxanthin consumption (Q2-Q4) was associated with lower OR for the risk of depression in nearly all subgroups when compared with the lowest quartile. The findings indicated no significant interaction between dietary consumption of zeaxanthin and lutein and risk of depression among most of the stratification factors (all p for interaction > 0.05), with the exception of total fat-based subgroup analysis (p for interaction < 0.05). For participants with an average daily total fat intake of $< 75\text{mg/day}$, the relationship between dietary lutein and zeaxanthin levels and depression was significant, but not for participants with an average daily total fat intake of $\geq 75\text{mg/day}$.

The results revealed that although the relationships were not statistically significant in certain categories, greater plasma lutein + zeaxanthin levels (Q2-Q4) tended to be related to lower ORs for depression in most subgroups compared to the lowest quartile. The findings provided by the interaction test indicated no significant interaction between the levels of plasma lutein + zeaxanthin and the other hierarchical factors (all p for interaction > 0.05), except for gender and total fat (p for interaction < 0.05). In female individuals, the relationship between plasma lutein and zeaxanthin levels and depression was more significant compared

to males. For participants with an average daily total fat intake of <75 mg/day, the relationship between plasma lutein and zeaxanthin levels and depression was more significant than for participants with an average daily total fat intake of ≥ 75 mg/day.

DISCUSSION

The relationship between lutein + zeaxanthin and depression has not been extensively studied; however, available evidence suggests that these carotenoids may exert protective effects on mental health. A recent systematic review and meta-analysis indicated a significant inverse association between dietary carotenoid intake, particularly lutein and zeaxanthin, and depressive symptoms.²⁰ Additionally, other studies have provided evidence supporting the neuroprotective role of lutein and zeaxanthin, showing their potential to improve cognitive function and brain health, which may indirectly contribute to lowering depression risk.²¹ These findings suggest that maintaining adequate levels of these carotenoids through diet could be an effective strategy in the prevention of depression. Further research is warranted to confirm these effects in diverse populations. In this community-based investigation, the relationship between plasma and alimentary levels of lutein and zeaxanthin with the risk of depression was analyzed in US adults. Our study's results demonstrated that appropriate increased dietary lutein + zeaxanthin intake and higher plasma lutein + zeaxanthin levels are associated with a lower risk of depression. Notably, these associations were maintained when the participants were sub-grouped by age, marital status, educational level, ethnicity, and the ratio of family income to the poverty level. Meanwhile, the results of our study showed that a variety of variables may be at play in the relationship between plasma and alimentary intake of lutein and zeaxanthin with the risk of depression. Nonetheless, the impact of energy and fat intake on depression should be further explored, as this could provide a more comprehensive understanding of the mechanism underlying the inhibitory effects of increasing dietary lutein and zeaxanthin against depression. For instance, a higher intake of energy and fat might be linked to better overall dietary habits, potentially benefiting mental health. Conversely, a lower intake of energy and fat could reflect a healthier lifestyle, which may also be associated with a reduced risk of depression. Therefore, investigating the interaction between these nutritional factors and depression risk could offer valuable insights for developing dietary recommendations aimed at preventing and treating depression. Collectively, our results highlight the need to maintain high plasma levels of lutein and zeaxanthin by consuming an appropriate amount of lutein and zeaxanthin to prevent depression. This study provides new insights into the relationship between nutrition and mental health, particularly concerning the

potential role of lutein and zeaxanthin in preventing and treating depression. The strong negative association observed between these carotenoids and depression risk highlights the potential for dietary interventions as a non-invasive and accessible means of improving mental health outcomes. Future public health strategies could benefit from incorporating recommendations for increased consumption of lutein and zeaxanthin-rich foods, particularly for populations at higher risk of depression.

Both a rise in oxidative stress and a fall in the levels of circulating antioxidants have been linked to depression. About a quarter of depression patients exhibit mild inflammation, and more than half of patients exhibit mildly elevated CRP levels.^{22,23} Many people suffering from depression may have inflammation as a contributing factor.²³ Some reasonable biological and physical mechanisms may link dietary and plasma lutein + zeaxanthin levels with depression. Carotenoids represent bioactive dietary ingredients that have aroused contemporary interest in their therapeutic effects on psychological well-being and the quality of sleep.²⁴ Numerous studies have investigated the relationship between lutein + zeaxanthin and cancer, revealing that they may have antioxidant properties that help control apoptotic cellular processes.^{25,26} Antioxidants can stop neuronal damage by inhibiting hydroxyl radicals and limiting lipid peroxidation to reduce oxidative damage.²⁷ Earlier research reported that lower levels of carotenoids are linked to an increase in depression symptoms.²⁸ Moreover, carotenoids can alter biological activities, exhibiting anti-inflammatory and antioxidant properties.²⁹ Two preclinical investigations indicated that supplementary β -carotene or zeaxanthin reduced inflammatory biomarkers such as tumor necrosis factor- α and interleukin-6, improving depressive-like traits in rats or mice with diabetes.^{30,31} Additionally, two pieces of research have demonstrated a decrease in antioxidant activity and depressive-like behavior in rodents: oxidative stress was lessened by supplemental β -carotene therapy by reducing plasma nitrite levels.³² The above arguments imply that depressive symptoms decrease as lutein/zeaxanthin increases. However, further study is urgently required to explore the underlying mechanism. Nevertheless, human trial data remains lacking. Hence, the conclusions of lutein + zeaxanthin reducing depression should be interpreted with caution until human trials are conducted.

The relationship between lutein/zeaxanthin and depression has not been extensively studied in the past. A previous study reported a positive relation between the amount of carotenoids consumed and the risk of developing depression or depression symptoms.¹⁴ In addition, a previous investigation has demonstrated a substantial negative relation between the risk of depression in participants with cardiovascular metabolic illnesses and the consumption of lutein + zeaxanthin.¹⁵ However, lutein/zeaxanthin did not appear to be linked to depression

symptoms in a cross-sectional study conducted among adult Americans.¹⁶ This is inconsistent with the research results of this study. This disparity may be attributed to differences in sample size and moderating variables. When further exploring the relationship between plasma and dietary lutein + zeaxanthin with depression, the results indicated stable outcomes regardless of subgroup analysis for age, ethnicity, education level, marital status, BMI, total energy and household income. However, the subgroup analysis revealed that gender showed a significant interaction with plasma lutein + zeaxanthin levels. The relationship between plasma lutein+ zeaxanthin and depression was more significant in female participants compared to males. Females are influenced by certain proteins in the process of regulating depressive emotions. These biological processes are related to immune inflammation control. However, men are more prone to experiencing imbalances during these processes.³³ Meanwhile, the subgroup analysis revealed that total fat showed a significant interaction with dietary lutein + zeaxanthin levels. For participants with an average daily total fat intake of <75mg/day, the relationship between dietary lutein and zeaxanthin levels and depression was significant, but not for participants with an average daily total fat intake of ≥ 75 mg/day. The reason may be related to the impact of fat type and concentration on the absorption of carotenoids. Multiple validations have confirmed that dietary fat promotes the absorption of carotenoids through an in vitro model.³⁴ Fat may also decrease the concentration of carotenoids through biological processes.³⁵ However, this result still requires further intervention experiments in the future to explore and confirm.

Our study has several advantages. First, this study examines the link between plasma lutein + zeaxanthin levels and depression risk in the US population. Secondly, it is the first research to explore the linear relationship between plasma and alimentary levels of lutein and zeaxanthin with the risk of depression. Prior research has investigated the connection between depression in American adults and alimentary lutein and zeaxanthin; however, the studies' sample sizes were not as large as ours. Second, our work used a sample approach to investigate the well-characterized NHANES datasets, allowing us to extrapolate our findings to the whole US population. Third, the linear associations between depression and plasma and dietary levels of lutein and zeaxanthin were investigated using a restricted cubic spline, which provides an excellent estimate of the actual link between exposure and the accompanying results since it is adept at finding linear correlations. Nevertheless, the limitations of the study should also be acknowledged. Firstly, the cross-sectional research approach limits the observation to the target population's health condition at a particular moment in time, and

causality cannot be determined. Second, residual confounders, such as geographic location, socioeconomic position, and medication usage, may also have had an impact on our findings.

Conclusion

The present results demonstrate the associations of higher dietary lutein + zeaxanthin intake and plasma lutein + zeaxanthin level with lower depression risk. The findings offer insights into how lutein + zeaxanthin nutrition can possibly be leveraged to reduce a person's risk of depression and improve health. However, our findings must be validated by multicenter, prospective, and large-scale studies. RCTs are still needed in the future to explore the effects of supplementing lutein + zeaxanthin on depression. We should aim for a healthy and balanced diet in terms of nutritional supplementation.

CONFLICT OF INTEREST AND FUNDING DISCLOSURE

The authors declare no conflict of interest.

No financial support was received from any institution or person for this study.

REFERENCES

1. Thapar A, Eyre O, Patel V, Brent D. Depression in young people. *Lancet*. 2022;400(10352):617-631. doi:10.1016/S0140-6736(22)01012-1
2. Freeman M. The world mental health report: transforming mental health for all. *World psychiatry: off j World Psychiatr Assoc (WPA)*. 2022;21:391-392. doi:10.1002/wps.21018
3. Singhal G, Baune BT. Microglia: an interface between the loss of neuroplasticity and depression. *Front Cell Neurosci*. 2017;11:270. doi:10.3389/fncel.2017.00270
4. Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the united states: results from the 2019 national survey on drug use and health. *Secur Res Hub Rep*. Published online January 1, 2020. <https://digitalcommons.fiu.edu/srhreports/health/health/32>
5. Guo D, Wang C, Liu X. Association of chronic diseases with depression in the united states, NHANES 2007-2018. *Psychol Health Med*. Published online November 21, 2023:1-14. doi:10.1080/13548506.2023.2277153
6. Hu PW, Zhang XL, Yan XT, Qi C, Jiang GJ. Association between depression and endometriosis using data from NHANES 2005-2006. *Sci Rep*. 2023;13(1):18708. doi:10.1038/s41598-023-46005-2
7. Nerurkar L, Siebert S, McInnes IB, Cavanagh J. Rheumatoid arthritis and depression: an inflammatory perspective. *Lancet Psychiatry*. 2019;6:164-173. doi:10.1016/S2215-0366(18)30255-4
8. Ronnstad ATM, Halling-Overgaard AS, Hamann CR, Skov L, Egeberg A, Thyssen JP. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic

- review and meta-analysis. *J Am Acad Dermatol.* 2018;79: 448-456.e30. doi:10.1016/j.jaad.2018.03.017
9. Hu PW, Zhang XL, Yan XT, Qi C, Jiang GJ. Association between depression and endometriosis using data from NHANES 2005-2006. *Sci Rep.* 2023;13(1):18708. doi:10.1038/s41598-023-46005-2
 10. Shen R, Zou T. The association between cardiovascular health and depression: results from the 2007–2020 NHANES. *Psychiat Res.* 2024;331:115663. doi:10.1016/j.psychres.2023.115663
 11. Ma J, Li K. Negative Association between Serum Vitamin D Levels and Depression in a Young Adult US Population: A Cross-Sectional Study of NHANES 2007-2018. *Nutrients.* 2023;15(13):2947. doi:10.3390/nu15132947
 12. Handelman GJ, Nightingale ZD, Lichtenstein AH, Schaefer EJ, Blumberg JB. Lutein and zeaxanthin concentrations in plasma after dietary supplementation with egg yolk². *Am J Clin Nutr.* 1999;70:247–251. doi:10.1093/ajcn.70.2.247
 13. Li D, Li Y. Associations of α -carotenoid and β -carotenoid with depressive symptoms in late midlife women. *J Affect Disorders.* 2019;256:424-430. doi:10.1016/j.jad.2019.06.003
 14. Milaneschi Y, Bandinelli S, Penninx BW, et al. The relationship between plasma carotenoids and depressive symptoms in older persons. *World J Biol Psychiatry: Off J World Fed Soc Biol Psychiatry.* 2012;13:588-598. doi:10.3109/15622975.2011.597876
 15. Liang J, Wang Y, Chen M. The association between dietary carotenoid intake and risk of depression among patients with cardiometabolic disease. *Int Heart J.* 2023;64:223-229. doi:10.1536/ihj.22-453
 16. Lin S, Shen Y. Dietary carotenoids intake and depressive symptoms in US adults, NHANES 2015–2016. *J Affect Disorders.* 2021;282:41-45. doi:10.1016/j.jad.2020.12.098
 17. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med.* 2001;16:606-613. doi:10.1046/j.1525-1497.2001.016009606.x
 18. Ba DM, Gao X, Al-Shaar L, et al. Mushroom intake and depression: a population-based study using data from the US national health and nutrition examination survey (NHANES), 2005–2016. *J Affect Disorders.* 2021;294:686-692. doi:10.1016/j.jad.2021.07.080
 19. Wang Y, Lopez JMS, Bolge SC, Zhu VJ, Stang PE. Depression among people with type 2 diabetes mellitus, US national health and nutrition examination survey (NHANES), 2005–2012. *BMC Psychiatry.* 2016;16(1):88. doi:10.1186/s12888-016-0800-2
 20. Yu Q, Xue F, Li Z, et al. Dietary intake of carotenoids and risk of depressive symptoms: a systematic review and meta-analysis. *Antioxid (Basel Switz).* 2022;11(11):2205. doi:10.3390/antiox11112205
 21. Mewborn CM, Lindbergh CA, Robinson TL, et al. Lutein and Zeaxanthin Are Positively Associated with Visual-Spatial Functioning in Older Adults: An fMRI Study. *Nutrients.* 2018;10(4):458. doi:10.3390/nu10040458
 22. Chamberlain SR, Cavanagh J, de Boer P, et al. Treatment-resistant depression and peripheral C-reactive protein. *Br J Psychiatry: J Ment Sci.* 2019;214(1):11-19. doi:10.1192/bjp.2018.66

23. Osimo EF, Baxter LJ, Lewis G, Jones PB, Khandaker GM. Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels. *Psychol Med.* 2019;49:1958-1970. doi:10.1017/S0033291719001454
24. Boozari B, Moradi S, Heydarpour F, et al. The association between carotenoid intake, mental health, and sleep quality among university students. *Sleep Breath = Schlaf Atm.* 2022;26:829-837. doi:10.1007/s11325-021-02420-1
25. Müller K, Carpenter KLH, Challis IR, Skepper JN, Arends MJ. Carotenoids induce apoptosis in the T-lymphoblast cell line jurkat E6.1. *Free Radical Res.* 2002;36:791-802. doi:10.1080/10715760290032539
26. Chew BP, Brown CM, Park JS, Mixter PF. Dietary lutein inhibits mouse mammary tumor growth by regulating angiogenesis and apoptosis. *Anticancer Res.* 2003;23:3333-3339.
27. Mayne ST. Antioxidant nutrients and chronic disease: Use of biomarkers of exposure and oxidative stress status in epidemiologic research. *J Nutr.* 2003;133:933S-940S. doi:10.1093/jn/133.3.933S
28. Black CN, Penninx BWJH, Bot M, et al. Oxidative stress, anti-oxidants and the cross-sectional and longitudinal association with depressive symptoms: results from the CARDIA study. *Transl Psychiatry.* 2016;6(2):e743. doi:10.1038/tp.2016.5
29. Stringham JM, Stringham NT, O'Brien KJ. Macular carotenoid supplementation improves visual performance, sleep quality, and adverse physical symptoms in those with high screen time exposure. *Foods.* 2017;6(7):47. doi:10.3390/foods6070047
30. Kim NR, Kim HY, Kim MH, Kim HM, Jeong HJ. Improvement of depressive behavior by sweetmeat pumpkin and its active compound, β -carotene. *Life Sci.* 2016;147:39-45. doi:10.1016/j.lfs.2016.01.036
31. Zhou X, Gan T, Fang G, Wang S, Mao Y, Ying C. Zeaxanthin improved diabetes-induced anxiety and depression through inhibiting inflammation in hippocampus. *Metab Brain Dis.* 2018;33:705-711. doi:10.1007/s11011-017-0179-x
32. Dhingra D, Bansal Y. Antidepressant-like activity of beta-carotene in unstressed and chronic unpredictable mild stressed mice. *J Funct Foods.* 2014;7:425-434. doi:10.1016/j.jff.2014.01.015
33. Xue X, Demirci D, Lenze EJ, et al. Sex differences in plasma proteomic markers in late-life depression. *Psychiat Res.* 2024;334:115773. doi:10.1016/j.psychres.2024.115773
34. Yao Y, Yang Z, Yin B, Goh HM, Toh DWK, Kim JE. Effects of dietary fat type and emulsification on carotenoid absorption: a randomized crossover trial *Am J Clin Nutr.* 2023;117:1017-1025. doi:10.1016/j.ajcnut.2023.03.011
35. Broekmans WMR, Klöpping-Ketelaars IAA, Weststrate JA, et al. Decreased carotenoid concentrations due to dietary sucrose polyesters do not affect possible markers of disease risk in humans. *J Nutr.* 2003;133:720-726. doi:10.1093/jn/133.3.720.

Not Proof Read

Table 1. General characteristics of the study population in the dietary lutein + zeaxanthin analysis

	Dietary lutein and zeaxanthin (μg)				<i>p</i> -value [§]
	Q1 (0.00-454.50)	Q2 (455.00-820.50)	Q3 (821.00-1548.50)	Q4 (1549.50-57188.00)	
N	1957	1955	1958	1959	
Age, years [†]	47.41 \pm 18.06	48.68 \pm 18.37	51.28 \pm 18.01	52.18 \pm 16.92	<0.001
Gender [†]					0.052
Male	900 (45.99%)	929 (47.52%)	984 (50.26%)	923 (47.12%)	
Female	1057 (54.01%)	1026 (52.48%)	974 (49.74%)	1036 (52.88%)	
Race					<0.001
Non-Hispanic White	865 (44.20%)	897 (45.88%)	851 (43.46%)	864 (44.10%)	
Black	481 (24.58%)	424 (21.69%)	414 (21.14%)	494 (25.22%)	
Other Hispanic	115 (5.88%)	128 (6.55%)	111 (5.67%)	115 (5.87%)	
Mexican American	313 (15.99%)	352 (18.01%)	357 (18.23%)	219 (11.18%)	
Other Race/Ethnicity	183 (9.35%)	154 (7.88%)	225 (11.49%)	267 (13.63%)	
Education level					<0.001
Less than high school	223 (11.40%)	189 (9.67%)	154 (7.87%)	111 (5.67%)	
High school	853 (43.61%)	768 (39.30%)	696 (35.55%)	521 (26.62%)	
College Graduate or above	880 (44.99%)	997 (51.02%)	1108 (56.59%)	1325 (67.71%)	
Marital status					<0.001
Married	955 (48.82%)	1033 (52.84%)	1130 (57.71%)	1082 (55.32%)	
Widowed	133 (6.80%)	166 (8.49%)	159 (8.12%)	143 (7.31%)	
Divorced	214 (10.94%)	191 (9.77%)	177 (9.04%)	253 (12.93%)	
Separated	81 (4.14%)	78 (3.99%)	64 (3.27%)	47 (2.40%)	
Never married	374 (19.12%)	322 (16.47%)	262 (13.38%)	286 (14.62%)	
Living with partner	199 (10.17%)	165 (8.44%)	166 (8.48%)	145 (7.41%)	
The ratio of family income to poverty	2.39 \pm 1.54	2.55 \pm 1.57	2.76 \pm 1.59	3.04 \pm 1.63	<0.001
BMI, kg/m ²	29.68 \pm 7.32	29.51 \pm 6.90	29.75 \pm 7.00	29.13 \pm 6.97	<0.05
Leisure exercise time, MET/week	1093.98 \pm 3701.52	1115.25 \pm 1853.51	1175.31 \pm 2179.99	1628.53 \pm 13712.45	0.127
Drinking					<0.001
No	1555 (79.46%)	1490 (76.21%)	1515 (77.37%)	1442 (73.61%)	
Yes	402 (20.54%)	465 (23.79%)	443 (22.63%)	517 (26.39%)	
Smoking status					<0.001
Never	993 (50.82%)	1053 (53.89%)	1102 (56.31%)	1134 (57.92%)	
Past	418 (21.39%)	495 (25.33%)	546 (27.90%)	558 (28.50%)	
Current	543 (27.79%)	406 (20.78%)	309 (15.79%)	266 (13.59%)	

MET (Metabolic Equivalent of Task) represents the amount of energy expended during physical activity. One MET is the amount of energy expended while sitting quietly. MET/week refers to the metabolic equivalents expended through physical activity in a week.

[†]Data are expressed as mean + standard deviation (SD)

[‡]n (%).

[§]p values indicate significant differences between the groups by ANOVA or chi-square tests.

Table 1. General characteristics of the study population in the dietary lutein + zeaxanthin analysis (cont.)

	Dietary lutein and zeaxanthin (μg)				<i>p</i> -value [§]
	Q1 (0.00-454.50)	Q2 (455.00-820.50)	Q3 (821.00-1548.50)	Q4 (1549.50-57188.00)	
Hypertension					0.054
No	1288 (66.12%)	1277 (65.42%)	1230 (62.88%)	1228 (62.75%)	
Yes	660 (33.88%)	675 (34.58%)	726 (37.12%)	729 (37.25%)	
Diabetes					0.215
No	1676 (87.70%)	1661 (86.83%)	1623 (85.42%)	1648 (86.33%)	
Yes	235 (12.30%)	252 (13.17%)	277 (14.58%)	261 (13.67%)	
Coronary heart disease					0.434
No	1864 (95.59%)	1873 (96.20%)	1861 (95.34%)	1861 (95.19%)	
Yes	86 (4.41%)	74 (3.80%)	91 (4.66%)	94 (4.81%)	
Depression					<0.001
No	1759 (89.88%)	1785 (91.30%)	1826 (93.26%)	1850 (94.44%)	
Yes	198 (10.12%)	170 (8.70%)	132 (6.74%)	109 (5.56%)	
Energy (kcal)	1764.56 \pm 736.17	2048.81 \pm 771.45	2180.66 \pm 839.90	2221.63 \pm 919.79	<0.001
Total fat (gm)	66.85 \pm 33.35	79.81 \pm 36.11	86.41 \pm 39.38	87.43 \pm 43.69	<0.001

MET (Metabolic Equivalent of Task) represents the amount of energy expended during physical activity. One MET is the amount of energy expended while sitting quietly. MET/week refers to the metabolic equivalents expended through physical activity in a week.

[†]Data are expressed as mean + standard deviation (SD)

[‡]n (%).

[§]p values indicate significant differences between the groups by ANOVA or chi-square tests.

Table 2. General characteristics of the study population in the plasma lutein + zeaxanthin analysis

	Plasma lutein and zeaxanthin (μg)				<i>p</i> -value [§]
	Q1 (0.030-0.195)	Q2 (0.197-0.283)	Q3 (0.285-0.399)	Q4 (0.401-3.270)	
N	1793	1863	1830	1838	
Age, years [†]	48.41 \pm 17.98	49.04 \pm 18.27	50.00 \pm 18.13	52.35 \pm 17.03	<0.001
Gender [†]					<0.05
Male	854 (47.63%)	918 (49.28%)	891 (48.69%)	826 (44.94%)	
Female	939 (52.37%)	945 (50.72%)	939 (51.31%)	1012 (55.06%)	
Race					<0.001
Non-Hispanic White	1085 (60.51%)	863 (46.32%)	701 (38.31%)	628 (34.17%)	
Black	343 (19.13%)	457 (24.53%)	448 (24.48%)	409 (22.25%)	
Other Hispanic	77 (4.29%)	100 (5.37%)	126 (6.89%)	130 (7.07%)	
Mexican American	184 (10.26%)	295 (15.83%)	365 (19.95%)	352 (19.15%)	
Other Race/Ethnicity	104 (5.80%)	148 (7.94%)	190 (10.38%)	319 (17.36%)	
Education level					<0.001
Less than high school	100 (5.58%)	139 (7.47%)	204 (11.15%)	194 (10.57%)	
High school	814 (45.40%)	713 (38.29%)	604 (33.01%)	512 (27.89%)	
College Graduate or above	879 (49.02%)	1010 (54.24%)	1022 (55.85%)	1130 (61.55%)	
Marital status					<0.001
Married	873 (48.72%)	955 (51.26%)	1011 (55.28%)	1117 (60.84%)	
Widowed	131 (7.31%)	132 (7.09%)	157 (8.58%)	139 (7.57%)	
Divorced	213 (11.89%)	211 (11.33%)	164 (8.97%)	189 (10.29%)	
Separated	69 (3.85%)	68 (3.65%)	61 (3.34%)	48 (2.61%)	
Never married	340 (18.97%)	318 (17.07%)	267 (14.60%)	224 (12.20%)	
Living with partner	166 (9.26%)	179 (9.61%)	169 (9.24%)	119 (6.48%)	
The ratio of family income to poverty	2.39 \pm 1.54	2.38 \pm 1.52	2.58 \pm 1.58	2.75 \pm 1.59	<0.001
BMI, kg/m ²	29.68 \pm 7.32	31.42 \pm 8.42	30.03 \pm 7.13	28.94 \pm 6.48	<0.001
Leisure exercise time, MET/week	994.37 \pm 1929.88	1225.71 \pm 2500.91	1594.80 \pm 14600.00	1271.83 \pm 3518.42	0.215
Drinking					<0.01
No	1422 (79.31%)	1439 (77.24%)	1364 (74.54%)	1389 (75.57%)	
Yes	371 (20.69%)	424 (22.76%)	466 (25.46%)	449 (24.43%)	
Smoking status					<0.001
Never	823 (45.95%)	952 (51.13%)	1042 (57.00%)	1191 (64.83%)	
Past	421 (23.51%)	500 (26.85%)	503 (27.52%)	471 (25.64%)	
Current	547 (30.54%)	410 (22.02%)	283 (15.48%)	175 (9.53%)	

MET (Metabolic Equivalent of Task) represents the amount of energy expended during physical activity. One MET is the amount of energy expended while sitting quietly. MET/week refers to the metabolic equivalents expended through physical activity in a week.

[†]Data are expressed as mean + standard deviation (SD)

[‡]n (%).

[§]p values indicate significant differences between the groups by ANOVA or chi-square tests.

Table 2. General characteristics of the study population in the plasma lutein + zeaxanthin analysis (cont.)

	Dietary lutein and zeaxanthin (μg)				<i>p</i> -value [§]
	Q1 (0.00-454.50)	Q2 (455.00-820.50)	Q3 (821.00-1548.50)	Q4 (1549.50-57188.00)	
Hypertension					<0.001
No	1078 (60.26%)	1228 (66.02%)	1195 (65.44%)	1208 (65.87%)	
Yes	711 (39.74%)	632 (33.98%)	631 (34.56%)	626 (34.13%)	
Diabetes					<0.001
No	1468 (83.98%)	1610 (88.56%)	1547 (86.38%)	1560 (87.49%)	
Yes	280 (16.02%)	208 (11.44%)	244 (13.62%)	223 (12.51%)	
Coronary heart disease					<0.01
No	1681 (94.02%)	1774 (95.58%)	1749 (95.99%)	1770 (96.51%)	
Yes	107 (5.98%)	82 (4.42%)	73 (4.01%)	64 (3.49%)	
Depression					<0.001
No	1574 (87.79%)	1732 (92.97%)	1707 (93.28%)	1745 (94.94%)	
Yes	219 (12.21%)	131 (7.03%)	123 (6.72%)	93 (5.06%)	
Energy (kcal)	2028.18 \pm 856.19	2089.15 \pm 841.49	2070.90 \pm 857.77	2021.58 \pm 773.48	<0.05
Total fat (gm)	79.28 \pm 39.65	82.00 \pm 38.69	80.13 \pm 40.16	78.58 \pm 37.10	<0.05

MET (Metabolic Equivalent of Task) represents the amount of energy expended during physical activity. One MET is the amount of energy expended while sitting quietly. MET/week refers to the metabolic equivalents expended through physical activity in a week.

[†]Data are expressed as mean + standard deviation (SD)

[‡]n (%).

[§]p values indicate significant differences between the groups by ANOVA or chi-square tests.

Table 3. Multivariate regression for associations of dietary consumption of lutein + zeaxanthin and plasma lutein + zeaxanthin level with risk of depression

Exposure	Non-adjusted [†]		Adjust I [‡]		Adjust II [§]	
	Odds ratio (95% CI)	<i>p</i> -value	Odds ratio (95% CI)	<i>p</i> -value	Odds ratio (95% CI)	<i>p</i> -value
Dietary lutein and zeaxanthin						
Per 1 SD increase in Dietary L+P	0.80 (0.70, 0.91)	<0.001	0.83 (0.73, 0.94)	<0.01	0.88 (0.78, 0.99)	<0.05
Q1	Reference (1.00)		Reference (1.00)		Reference (1.00)	
Q2	0.85 (0.68, 1.05)	0.128	0.90 (0.73, 1.12)	0.361	0.94 (0.75, 1.18)	0.600
Q3	0.64 (0.51, 0.81)	<0.001	0.73 (0.58, 0.93)	<0.01	0.79 (0.62, 1.01)	0.065
Q4	0.52 (0.41, 0.67)	<0.001	0.59 (0.46, 0.76)	<0.001	0.68 (0.52, 0.89)	<0.01
<i>p</i> for trend	<0.001		<0.001		<0.01	
Plasma Lutein and zeaxanthin (nmol/L)						
Per 1 SD increase in Plasma L+P	0.61 (0.53, 0.70)	<0.001	0.62 (0.54, 0.71)	<0.001	0.74 (0.65, 0.85)	<0.001
Q1	Reference (1.00)		Reference (1.00)		Reference (1.00)	
Q2	0.54 (0.43, 0.68)	<0.001	0.55 (0.43, 0.69)	<0.001	0.62 (0.49, 0.79)	<0.001
Q3	0.52 (0.41, 0.65)	<0.001	0.53 (0.42, 0.67)	<0.001	0.68 (0.53, 0.88)	<0.01
Q4	0.38 (0.30, 0.49)	<0.001	0.40 (0.30, 0.52)	<0.001	0.58 (0.44, 0.76)	<0.001
<i>p</i> for trend	<0.001		<0.001		<0.001	

L+P, lutein + zeaxanthin; OR, odds ratio; 95% CI, 95% confidence intervals

[†]The non-adjusted model was not adjusted for any factor

[‡]Model I was adjusted for age, gender, race, education level, and marital status

[§]Model II was adjusted for age, gender, race, education level, energy, marital status, total fat, BMI, Smoking status, leisure exercise time, hypertension, diabetes, coronary heart disease, the ratio of family income to poverty, and drinking.

Table 4. Association between dietary lutein + zeaxanthin intake and depression across different subgroups

	Dietary lutein and zeaxanthin (μg)				<i>p</i> for trend	<i>p</i> for interaction
	Q1 (0.00-454.50)	Q2 (455.00-820.50)	Q3 (821.00-1548.50)	Q4 (1549.50-57188.00)		
Age						0.152
<60	Reference (1.00)	1.06 (0.81, 1.38) 0.661	0.75 (0.55, 1.02) 0.064	0.74 (0.54, 1.02) 0.067	<0.05	
\geq 60	Reference (1.00)	0.77 (0.50, 1.19) 0.234	0.90 (0.59, 1.37) 0.614	0.59 (0.36, 0.94) <0.05	0.067	
Gender						0.836
Male	Reference (1.00)	0.98 (0.69, 1.41) 0.925	0.90 (0.62, 1.31) 0.591	0.67 (0.44, 1.03) 0.068	0.076	
Female	Reference (1.00)	0.98 (0.73, 1.31) 0.881	0.75 (0.54, 1.04) 0.087	0.71 (0.50, 0.99) <0.05	<0.05	
Race						0.159
Non-Hispanic white	Reference (1.00)	0.99 (0.71, 1.38) 0.962	0.65 (0.44, 0.96) <0.05	0.61 (0.40, 0.93) <0.05	<0.01	
Others	Reference (1.00)	0.95 (0.69, 1.29) 0.732	0.94 (0.68, 1.30) 0.722	0.76 (0.54, 1.07) 0.119	0.147	
Education level						0.607
Less than high school	Reference (1.00)	1.06 (0.53, 2.14) 0.865	1.02 (0.46, 2.27) 0.966	0.91 (0.38, 2.14) 0.823	0.829	
High school	Reference (1.00)	1.09 (0.78, 1.53) 0.623	0.95 (0.65, 1.37) 0.773	0.80 (0.52, 1.22) 0.296	0.293	
College Graduate or above	Reference (1.00)	0.84 (0.59, 1.18) 0.316	0.66 (0.46, 0.96) <0.05	0.56 (0.39, 0.82) <0.01	<0.01	
Marital status						0.341
Married/Living with partner	Reference (1.00)	0.88 (0.64, 1.20) 0.417	0.81 (0.58, 1.13) 0.211	0.53 (0.35, 0.78) <0.01	<0.01	
Widowed/Divorced/ Separated	Reference (1.00)	1.10 (0.72, 1.67) 0.652	0.97 (0.62, 1.53) 0.911	0.93 (0.59, 1.46) 0.751	0.663	
Never Married	Reference (1.00)	1.00 (0.59, 1.68) 0.992	0.54 (0.28, 1.04) 0.065	0.85 (0.47, 1.52) 0.575	0.266	
BMI						0.716
<25	Reference (1.00)	0.78 (0.48, 1.25) 0.294	0.72 (0.43, 1.23) 0.232	0.68 (0.39, 1.21) 0.188	0.159	
\geq 25	Reference (1.00)	1.03 (0.79, 1.33) 0.835	0.84 (0.63, 1.11) 0.214	0.70 (0.52, 0.94) <0.05	<0.05	
The ratio of family income to poverty						0.778
<2.34	Reference (1.00)	0.98 (0.74, 1.30) 0.888	0.81 (0.60, 1.11) 0.197	0.60 (0.42, 0.85) <0.01	<0.01	
\geq 2.34	Reference (1.00)	0.84 (0.54, 1.30) 0.424	0.82 (0.52, 1.29) 0.390	0.73 (0.46, 1.16) 0.182	0.198	
Total energy (kcal)						0.193
<2000	Reference (1.00)	1.01 (0.76, 1.34) 0.932	0.69 (0.49, 0.97) <0.05	0.64 (0.45, 0.92) <0.05	<0.01	
\geq 2000	Reference (1.00)	0.99 (0.67, 1.46) 0.970	1.00 (0.68, 1.48) 0.993	0.81 (0.53, 1.24) 0.332	0.358	
Total fat (g)						<0.01
<75	Reference (1.00)	1.11 (0.83, 1.49) 0.465	0.61 (0.42, 0.90) <0.05	0.67 (0.46, 0.98) <0.05	<0.01	
\geq 75	Reference (1.00)	0.88 (0.61, 1.27) 0.487	1.02 (0.72, 1.47) 0.897	0.74 (0.50, 1.09) 0.126	0.239	

Adjusted for age, gender, race, education level, energy, marital status, total fat, BMI, Smoking status, leisure exercise time, hypertension, diabetes, coronary heart disease, the ratio of family income to poverty, and drinking.

Table 5. Association between plasma levels of lutein and zeaxanthin and depression across different subgroups

	Dietary lutein and zeaxanthin (μg)				<i>p</i> for trend	<i>p</i> for interaction
	Q1 (0.030-0.195)	Q2 (0.197-0.283)	Q3 (0.285-0.399)	Q4 (0.401-3.270)		
Age						0.842
<60	Reference (1.00)	0.60 (0.45, 0.80) <0.001	0.73 (0.54, 0.98) <0.05	0.59 (0.42, 0.83) <0.01	<0.01	
\geq 60	Reference (1.00)	0.69 (0.44, 1.07) 0.097	0.63 (0.39, 1.00) <0.05	0.58 (0.36, 0.93) <0.05	<0.05	
Gender						<0.05
Male	Reference (1.00)	0.80 (0.56, 1.15) 0.224	0.53 (0.34, 0.80) <0.01	0.67 (0.44, 1.04) 0.077	<0.05	
Female	Reference (1.00)	0.52 (0.38, 0.72) <0.001	0.80 (0.58, 1.10) 0.165	0.54 (0.38, 0.78) <0.001	<0.01	
Race						0.078
Non-Hispanic white	Reference (1.00)	0.77 (0.55, 1.08) 0.128	0.55 (0.36, 0.85) <0.01	0.46 (0.28, 0.77) <0.01	<0.001	
Others	Reference (1.00)	0.55 (0.39, 0.77) <0.001	0.76 (0.55, 1.04) 0.088	0.63 (0.44, 0.89) <0.01	0.059	
Education level						0.754
Less than high school	Reference (1.00)	0.73 (0.29, 1.80) 0.494	0.67 (0.29, 1.58) 0.363	0.69 (0.29, 1.63) 0.396	0.444	
High school	Reference (1.00)	0.62 (0.43, 0.89) <0.05	0.82 (0.56, 1.20) 0.310	0.71 (0.46, 1.10) 0.128	0.153	
College Graduate or above	Reference (1.00)	0.60 (0.42, 0.84) <0.01	0.62 (0.43, 0.89) <0.05	0.45 (0.30, 0.68) <0.001	<0.001	
Marital status						0.667
Married/Living with partner	Reference (1.00)	0.70 (0.50, 0.98) <0.05	0.70 (0.49, 1.00) <0.05	0.54 (0.37, 0.81) <0.01	<0.01	
Widowed/Divorced/ Separated	Reference (1.00)	0.57 (0.37, 0.89) <0.05	0.80 (0.51, 1.24) 0.308	0.60 (0.37, 0.98) <0.05	0.082	
Never Married	Reference (1.00)	0.62 (0.36, 1.06) 0.082	0.54 (0.28, 1.03) 0.062	0.82 (0.43, 1.56) 0.539	0.256	
BMI						0.453
<25	Reference (1.00)	0.59 (0.36, 0.96) <0.05	0.49 (0.28, 0.83) <0.01	0.43 (0.24, 0.77) <0.01	<0.01	
\geq 25	Reference (1.00)	0.60 (0.45, 0.79) <0.001	0.72 (0.54, 0.96) <0.05	0.63 (0.46, 0.87) <0.01	<0.01	
The ratio of family income to poverty						0.683
<2.34	Reference (1.00)	0.65 (0.48, 0.88) <0.01	0.72 (0.52, 1.00) <0.05	0.65 (0.45, 0.93) <0.05	<0.05	
\geq 2.34	Reference (1.00)	0.60 (0.38, 0.94) <0.05	0.67 (0.43, 1.04) 0.071	0.44 (0.27, 0.73) <0.01	<0.01	
Total energy (kcal)						0.427
<2000	Reference (1.00)	0.54 (0.39, 0.74) <0.001	0.69 (0.50, 0.96) <0.05	0.58 (0.41, 0.83) <0.01	<0.01	
\geq 2000	Reference (1.00)	0.74 (0.51, 1.06) 0.103	0.65 (0.43, 0.96) <0.05	0.57 (0.37, 0.89) <0.05	<0.01	
Total fat (g)						<0.05
<75	Reference (1.00)	0.48 (0.34, 0.68) <0.001	0.71 (0.51, 1.00) <0.05	0.53 (0.36, 0.77) <0.01	<0.01	
\geq 75	Reference (1.00)	0.81 (0.57, 1.13) 0.2086	0.59 (0.41, 0.87) <0.01	0.66 (0.44, 0.99) <0.05	<0.05	

Adjusted for age, gender, race, education level, energy, marital status, total fat, BMI, Smoking status, leisure exercise time, hypertension, diabetes, coronary heart disease, the ratio of family income to poverty, and drinking.




Figure 1. Flow chart of participant selection for the study population, NHANES 2005–2006 and 2017-2018.




Figure 2. The dose-response association between dietary lutein + zeaxanthin intake and depression




Figure 3. The dose-response association between plasma lutein + zeaxanthin level and depression